Immunopharmacology of thymosin α1 and cytokine synergy

Annals of the New York Academy of Sciences

Volumn 1112, Issue , 2007, Pages 235-244

  Naylor, Paul H ^a   Quadrini, Karen ^a   Garaci, Enrico ^b   Rasi, Guido ^b   Hadden, John W ^a  

^a IRX Therapeutics Inc   (United States)

^b CNR   (Italy)

Author keywords

IRX 2; T lymphocytes; Thymosin 1; Thymus

Indexed keywords

1 (5 ISOQUINOLINYLSULFONYL) 2 METHYLPIPERAZINE H 7; CYCLOPHOSPHAMIDE; CYTOKINE; INTERLEUKIN 2; IRX 2; IRX 3; PROTEIN KINASE C INHIBITOR; THYMOSIN ALPHA1; UNCLASSIFIED DRUG; DRUG DERIVATIVE; PROTEIN KINASE C; THYMOSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CANCER SURVIVAL; CELLULAR IMMUNITY; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE MODEL; HUMAN; IMMUNOPHARMACOLOGY; LEWIS CARCINOMA; MALE; MONOTHERAPY; MOUSE; NONHUMAN; ANIMAL; ARTICLE; DRUG EFFECT; DRUG POTENTIATION; EXPERIMENTAL NEOPLASM; LUNG TUMOR; METABOLISM;

ANIMALIA; MUS;

ANIMALS; CYTOKINES; DRUG SYNERGISM; HUMANS; IMMUNITY, CELLULAR; LUNG NEOPLASMS; MICE; NEOPLASMS, EXPERIMENTAL; PROTEIN KINASE C; THYMOSIN;

EID: 35348935978     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1415.036     Document Type: Conference Paper

References (25)

1. MCINTIRE, K.R., S. SELL & J.F. MILLER. 1964. Pathogenesis of the post-neonatal thymectomy wasting syndrome. Nature 204: 151.
2. RIBATTI, D. 2006. The fundamental contribution of Robert A. Good to the discovery of the crucial role of thymus in mammalian immunity. Immunology 119: 291.
3. LOW, T.L., G.B. THURMAN, M. MCADOO, et al. 1979. The chemistry and biology of thymosin. I. Isolation, characterization, and biological activities of thymosin alpha1 and polypeptide beta1 from calf thymus. J. Biol. Chem. 254: 981.
4. NAYLOR, P.H. & A.L. GOLDSTEIN. 1988. Thymosin modulates immune and endocrine events. Prog. Clin. Biol. Res. 256: 489.
5. OATES, K.K., G.T. GINSBURG, P.H. NAYLOR, et al. 1988. Identification and distribution of thymosin alpha 1-like immunoreactivity. Dev. Comp. Immunol. 12: 397.
6. OATES, K.K., P.H. NAYLOR & A.L. GOLDSTEIN. 1987. Localization of thymosin alpha 1 production to thymus medullary epithelial cells by use of monoclonal antibodies. Hybridoma 6: 47.
7. SARANDESES, C.S., G. COVELO, C. DIAZ- JULLIEN & M. FREIRE. 2003. Prothymosin alpha is processed to thymosin alpha 1 and thymosin alpha 11 by a lysosomal asparaginyl endopeptidase. J. Biol. Chem. 278: 13286.
8. GOLDSTEIN, A.L., R.S. SCHULOF, P.H. NAYLOR & N.R. HALL. 1986. Thymosins and anti-thymosins: properties and clinical applications. Med. Oncol. Tumor Pharmacother. 3: 211.
9. HADDEN, J.W. 2001. Aspects of the immunopharmacology of thymosin a1. Clin. Appl. Immunol. Rev. 1: 187.
10. COTO, J.A., E.M. HADDEN, M. SAURO, et al. 1992. Interleukin 1 regulates secretion of zinc-thymulin by human thymic epithelial cells and its action on T-lymphocyte proliferation and nuclear protein kinase C. Proc. Natl. Acad. Sci. USA 89: 7752.
11. BAUMANN, C.A., M. BADAMCHIAN & A.L. GOLDSTEIN. 2000. Thymosin alpha1 is a time and dose-dependent antagonist of dexamethasone-induced apoptosis of murine thymocytes in vitro. Int. J. Immunopharmacol. 22: 1057.
12. ZHANG, P., J. CHAN, A.M. DRAGOI, et al. 2005. Activation of IKK by thymosin alpha1 requires the TRAF6 signalling pathway. EMBO Rep. 6: 531.
13. HADDEN, J., E. VERASTEGUI, J.L. BARRERA, et al. 2003. A trial of IRX-2 in patients with squamous cell carcinomas of the head and neck. Int. Immunopharmacol. 3: 1073.
14. RUSSELL, D.H., N.E. ZORN, A.R. BUCKLEY, et al. 1990. Prolactin and known modulators of rat splenocytes activate nuclear protein kinase C. Eur. J. Pharmacol. 188: 139.
15. LEICHTLING, K.D., S.A. SERRATE & M.B. SZTEIN. 1990. Thymosin alpha 1 modulates the expression of high affinity interleukin-2 receptors on normal human lymphocytes. Int. J. Immunopharmacol. 12: 19.
16. ROMANI, L., F. BISTONI, R. GAZIANO, et al. 2004. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood 103: 4232.
17. ROMANI, L., F. BISTONI, K. PERRUCCIO, et al. 2006. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood 108: 2265.
18. GARACI, E., F. PICA, P. SINIBALDI- VALLEBONA, et al. 2003. Thymosin alpha(1) in combination with cytokines and chemotherapy for the treatment of cancer. Int. Immunopharmacol. 3: 1145.
19. GIULIANI, C., G. NAPOLITANO, A. MASTINO, et al. 2000. Thymosin-alpha1 regulates MHCclass I expression in FRTL-5 cells at transcriptional level. Eur. J. Immunol. 30: 778.
20. SZTEIN, M.B. & S.A. SERRATE. 1989. Characterization of the immunoregulatory properties of thymosin alpha 1 on interleukin-2 production and interleukin-2 receptor expression in normal human lymphocytes. Int. J. Immunopharmacol. 11: 789.
21. SZTEIN, M.B., S.A. SERRATE & A.L. GOLDSTEIN. 1986. Modulation of interleukin 2 receptor expression on normal human lymphocytes by thymic hormones. Proc. Natl. Acad. Sci. USA 83: 6107.
22. SODHI, A. & S. PAUL. 2002. Involvement of mitogen-activated protein kinases in the signal transduction pathway of bone marrow-derived macrophage activation in response to in vitro treatment with thymosin alpha 1. Int. Immunopharmacol. 2: 47.
23. MASTINO, A., C. FAVALLI, S. GRELLI, et al. 1992. Combination therapy with thymosin alpha 1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice. Int. J. Cancer 50: 493.
24. HADDEN, J.W., A. SAHA, M. SOSA & E.M. HADDEN. 1995. Immunotherapy with natural interleukins and/or thymosin alpha 1 potently augments T-lymphocyte responses of hydrocortisone-treated aged mice. Int. J. Immunopharmacol. 17: 821.
25. MACHIELS, J.P., R.T. REILLY, L.A. EMENS, et al. 2001. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 61: 3689.